Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737297 | 0.83 | HSP90AA1 (0.56) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL28316950 | 0.77 | GFER (0.44) | CYP2A6ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL18878582 | 0.77 | CYP2A6 (0.41) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL6121215 | 0.76 | CYP2A6 (0.39) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL16279422 | 0.74 | KDM4E (0.38) | CYP2A6ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL18791452 | 0.74 | HDAC3 (0.49) | CYP2A6MAPTKDM4EMEN1KMT2A | |
| SCHEMBL2093940 | 0.74 | CYP2A6 (0.38) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL4283955 | 0.74 | MAPT (0.45) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL16693109 | 0.74 | CYP2A6 (0.38) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL5646366 | 0.74 | CYP2A6 (0.38) | HSP90AA1CYP2A6ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017069980-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | disclosed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | disclosed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | HSP90AA1 4663/4885CYP2A6 1601/4885ALDH1A1 2907/4885 |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | HSP90AA1 2777/4885CYP2A6 112/4885ALDH1A1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.